Immutep Gets Positive Feedback From FDA On Late-Stage Clinical Development Of Eftilagimod Alfa

Immutep Limited (IMMP) received positive and constructive feedback from the US FDA regarding the future clinical development of its eftilagimod alfa, in combination with MSD's KEYTRUDA, for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients with PD-L1 expression below 1. Based on encouraging TACTI-003 Phase IIb trial data, the FDA acknowledged the combination's potential to address a high unmet medical need in this specific patient segment and expressed support for its further development, signaling a clearer path forward for the immunotherapy.

Analysis

Immutep Limited has achieved a significant regulatory milestone, receiving positive feedback from the U.S. FDA for its lead drug candidate, eftilagimod alfa (efti). This feedback specifically pertains to the development of efti in combination with MSD's KEYTRUDA for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in patients with low PD-L1 expression (CPS < 1). The FDA's support, based on encouraging data from the TACTI-003 Phase IIb trial, validates the drug's potential in a patient segment with a high unmet medical need. This development materially de-risks the clinical pathway for efti and, as stated by the CEO, positions Immutep to advance its collaborative and clinical development strategies from a stronger negotiating position. The agency's explicit support for further development provides a clearer path towards a potential pivotal trial and eventual commercialization.

Key Decisions for Investors

• This positive FDA feedback should be viewed as a significant de-risking event for Immutep's lead asset, potentially justifying a re-evaluation of the company's valuation based on a clearer regulatory pathway.
• Investors should now focus on upcoming catalysts, particularly any announcements regarding the design of a pivotal trial or the establishment of a formal partnership for the combination therapy with KEYTRUDA.
• The specific focus on the PD-L1 low HNSCC population represents a key strategic advantage, as it targets a high-need segment where existing immunotherapies are less effective, potentially creating a well-defined and valuable market opportunity.